Log In
Print
BCIQ
Print
Print this Print this
 

Epi proColon 2.0

  Manage Alerts
Collapse Summary General Information
Company Epigenomics AG
DescriptionSecond-generation colorectal cancer test based on detection of methylated DNA of the Septin 9 gene in blood plasma by real-time PCR
Molecular Target Septin 9 (SEPT9)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect colorectal cancer
Regulatory Designation

U.S. - Priority Review (Detect colorectal cancer)

Partner

Abbott Laboratories; BioChain Institute Inc.; Gamma-Dynacare Medical Laboratories; Polymedco Inc.; Quest Diagnostics Inc.; Sysmex Corp.; VSA Alta Complejidad S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today